NEW YORK – Theradiag this week said that it has applied CE marking for its i-Track automated analyzer for biotherapy monitoring.
The analyzer is manufactured by UK-based Immunodiagnostic Systems for Theradiag and leverages chemiluminescence-based technology. The two companies reached a deal earlier this year giving Marne-la-Vallée, France-based Theradiag access to the platform, formerly called the iDS-i10 automation system.
Theradiag has registered i-Track with the French National Drug and Health Product Safety Agency for marketing. The i-Track is expected to launch in the first half of 2020, Theradiag CEO Bertrand de Castelnau said in a statement.